The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A first-in-human phase I/Ib study of receptor tyrosine kinase (RTK) inhibitor, MGCD516, in patients with advanced solid tumors.
 
Gary K. Schwartz
Honoraria - AstraZeneca; Boehringer Ingelheim; Novartis
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Novartis
 
Douglas Adkins
Research Funding - AstraZeneca (Inst); Celgene (Inst); Galera Therapeutics (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Soligenix (Inst); VentiRx (Inst)
 
Rebecca Suk Heist
Consulting or Advisory Role - Boehringer Ingelheim; Momenta Pharmaceuticals
 
Maura Abbott
No Relationships to Disclose
 
Stephanie L. Barber
No Relationships to Disclose
 
Richard C. Chao
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
 
Saskia T.C. Neuteboom
Employment - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
 
Isan Chen
Employment - Mirati Therapeutics
Leadership - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics
Patents, Royalties, Other Intellectual Property - Aragon Pharmaceuticals
 
James Christensen
Employment - Mirati Therapeutics
Leadership - Mirati Therapeutics
Stock and Other Ownership Interests - Mirati Therapeutics; Pfizer
Patents, Royalties, Other Intellectual Property - Mirati Therapeutics; Pfizer
 
Todd Michael Bauer
Research Funding - Mirati Therapeutics (Inst)